Bradley C Holland1, Zubin Shetty2, Shaheen Alanee3. 1. Department of Surgery, Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, USA. 2. Department of Urology, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA. 3. Department of Urology, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA. salanee@siumed.edu.
Abstract
PURPOSE OF REVIEW: Targeted therapy for genitourinary cancer is being used at an increasing rate. These medications show great survival benefit but are relatively lacking in long-term adverse effect data. With increasing survivability, measures to improve quality of life must be considered for GU cancer and a large proponent of this is sexual function. RECENT FINDINGS: mTOR inhibitors have shown an effect on testosterone levels and may have a link to abnormal semen parameters. Tyrosine kinase inhibitors (TKIs) have shown no adverse sexual outcomes in the literature. There are laboratory links to tyrosine kinases having a beneficial effect on erectile and sexual function. Possible sexual side effects must be discussed with patients receiving a diagnosis of cancer. Further research is required to determine the exact mechanisms and outcomes of sexual function with new and emerging targeted therapy.
PURPOSE OF REVIEW: Targeted therapy for genitourinary cancer is being used at an increasing rate. These medications show great survival benefit but are relatively lacking in long-term adverse effect data. With increasing survivability, measures to improve quality of life must be considered for GU cancer and a large proponent of this is sexual function. RECENT FINDINGS:mTOR inhibitors have shown an effect on testosterone levels and may have a link to abnormal semen parameters. Tyrosine kinase inhibitors (TKIs) have shown no adverse sexual outcomes in the literature. There are laboratory links to tyrosine kinases having a beneficial effect on erectile and sexual function. Possible sexual side effects must be discussed with patients receiving a diagnosis of cancer. Further research is required to determine the exact mechanisms and outcomes of sexual function with new and emerging targeted therapy.
Authors: Behrooz K Shamloo; Pankdeep Chhabra; Andrew N Freedman; Arnold Potosky; Jennifer Malin; Sheila Weiss Smith Journal: Drug Saf Date: 2012-06-01 Impact factor: 5.606
Authors: Eva Johansson; Gunnar Steineck; Lars Holmberg; Jan-Erik Johansson; Tommy Nyberg; Mirja Ruutu; Anna Bill-Axelson Journal: Lancet Oncol Date: 2011-08-05 Impact factor: 41.316
Authors: D K Montague; J H Barada; A M Belker; L A Levine; P W Nadig; C G Roehrborn; I D Sharlip; A H Bennett Journal: J Urol Date: 1996-12 Impact factor: 7.450
Authors: Suji Lee; Maria Coco; Stuart M Greenstein; Richard S Schechner; Vivian A Tellis; Daniel G Glicklich Journal: Clin Transplant Date: 2005-04 Impact factor: 2.863
Authors: Andrew J Weickhardt; Robert C Doebele; W Thomas Purcell; Paul A Bunn; Ana B Oton; Micol S Rothman; Margaret E Wierman; Tony Mok; Sanjay Popat; Julie Bauman; Jorge Nieva; Silvia Novello; Sai-Hong Ignatius Ou; D Ross Camidge Journal: Cancer Date: 2013-04-12 Impact factor: 6.860
Authors: Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer Journal: Lancet Date: 2016-03-04 Impact factor: 79.321